81 results
8-K
EX-99.1
NAVB
Navidea Biopharmaceuticals, Inc.
1 Dec 23
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
11:49am
pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review
8-K
EX-99.1
NAVB
Navidea Biopharmaceuticals, Inc.
28 Jul 23
Departure of Directors or Certain Officers
5:10pm
control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report
8-K
EX-99.1
NAVB
Navidea Biopharmaceuticals, Inc.
13 Jul 23
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
5:27pm
ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed
8-K
EX-99.1
NAVB
Navidea Biopharmaceuticals, Inc.
6 Jul 23
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
4:39pm
internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual
8-K
EX-99.1
0ogvo697kbl61g
16 Jun 23
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment
5:24pm
8-K
EX-99.1
u1lbp12k lcjjo2z
16 Jun 23
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
5:22pm
8-K
EX-99.2
cobpe6dgtx
2 Jun 23
Entry into a Material Definitive Agreement
6:14pm
8-K
EX-99.1
vt3k nwfo9knw58aryb
2 Jun 23
Entry into a Material Definitive Agreement
6:14pm
8-K
EX-99.1
tf89hdyj34vfkkpnla
25 May 23
Entry into a Material Definitive Agreement
4:14pm
8-K
EX-99.1
jolq3butxjah wz4
28 Apr 23
Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit
10:56am
424B5
mvvg8yto2m0x 9czxk
28 Apr 23
Prospectus supplement for primary offering
10:55am
8-K
EX-99.1
n5hrg1cytqoix0 s2y8
13 Apr 23
Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694
5:24pm
8-K
EX-10.1
3bz2i ahvfk
13 Apr 23
Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694
5:24pm
8-K
EX-99.1
4xm18s6 e43bv
31 Mar 23
Departure of Directors or Certain Officers
5:20pm
8-K
EX-99.1
yzoap
15 Nov 22
Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
4:00pm
8-K
EX-99.1
524z2b0u4r6ef
30 Sep 22
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders
8:45am